BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36175804)

  • 1. The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death.
    Zhang Z; Shen C; Zhou F
    Med Oncol; 2022 Sep; 39(12):221. PubMed ID: 36175804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
    Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
    Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
    Jing W; Shuo L; Yingru X; Min M; Runpeng Z; Jun X; Dong H
    Biochem Biophys Res Commun; 2019 Oct; 519(1):41-45. PubMed ID: 31481232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huaier Extract Induces Autophagic Cell Death by Inhibiting the mTOR/S6K Pathway in Breast Cancer Cells.
    Wang X; Qi W; Li Y; Zhang N; Dong L; Sun M; Cun J; Zhang Y; Lv S; Yang Q
    PLoS One; 2015; 10(7):e0131771. PubMed ID: 26134510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
    Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
    Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
    Wu MH; Chiu YF; Wu WJ; Wu PL; Lin CY; Lin CL; Hsieh YH; Liu CJ
    Environ Toxicol; 2018 Dec; 33(12):1237-1244. PubMed ID: 30187994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
    Chen MY; Hsu CH; Setiawan SA; Tzeng DTW; Ma HP; Ong JR; Chu YC; Hsieh MS; Wu ATH; Tzeng YM; Yeh CT
    Phytomedicine; 2023 Jan; 108():154478. PubMed ID: 36265255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
    Nour MA; Kheradmand F; Rasmi Y; Baradaran B
    Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
    Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
    Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
    Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
    J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.
    El-Sewedy T; Salama AF; Mohamed AE; Elbaioumy NM; El-Far AH; Albalawi AN; Elmetwalli A
    BMC Complement Med Ther; 2023 Sep; 23(1):329. PubMed ID: 37726740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
    Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
    J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
    Romito I; Porru M; Braghini MR; Pompili L; Panera N; Crudele A; Gnani D; De Stefanis C; Scarsella M; Pomella S; Levi Mortera S; de Billy E; Conti AL; Marzano V; Putignani L; Vinciguerra M; Balsano C; Pastore A; Rota R; Tartaglia M; Leonetti C; Alisi A
    J Exp Clin Cancer Res; 2021 Nov; 40(1):364. PubMed ID: 34784956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
    Cheng Z; Ni Q; Qin L; Shi Y
    Braz J Med Biol Res; 2021; 54(9):e10390. PubMed ID: 34076140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.